Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2011 Apr;20(4):507-18. doi: 10.1517/13543784.2011.562192.

New phosphatidylinositol 3-kinase inhibitors for cancer.

Author information

1
University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA.

Abstract

INTRODUCTION:

Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins important to cancer development or survival. The PI3K signaling axis is an important pathway involved in myriad human malignancies. Inhibition of this axis is a promising therapeutic approach for several cancers.

AREAS COVERED:

This article reviews current literature and recent conference proceedings to analyze the rationale for targeting PI3K and its downstream effectors in cancer. Preclinical and clinical results of several PI3K and PI3K--mammalian target of rapamycin (mTOR) inhibitors in early clinical trials, as single agents and in combination with other drugs, are discussed. Thus far, clinical results have been mixed.

EXPERT OPINION:

The clinical utility of PI3K and PI3K--mTOR inhibitors will depend on appropriate selection of patients. Mutations in the PI3K pathway may predict sensitivity to PI3K inhibition but they are not reliable biomarkers at this point. Efforts to define predictive biomarkers will probably be the key to finding therapeutic uses for this novel class of anticancer agents.

PMID:
21395485
DOI:
10.1517/13543784.2011.562192
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center